CASI Pharmaceuticals jumps after receiving acquisition proposal for entire China business
CASI Pharmaceuticals (NASDAQ:CASI) surged in extended trading on Wednesday after the company said it has received a preliminary proposal from CEO Wei-Wu-He to acquire its entire business operations in China. Shares of the China-based biotech were up nearly 80% at $6.41 in trading after the bell. According to the proposal,Continue Reading